血液腫瘍に対するtisagenlecleucel（商品名Kymriah）とaxicabtagene ciloleucel （同Yescarta）
First two CAR-T cell medicines recommended for approval in the European Union
The European Medicines Agency (EMA) has recommended the first two marketing authorisations for chimeric antigen receptors (CAR) T-cells medicines in the European Union (EU). Kymriah (tisagenlecleucel) and Yescarta (axicabtagene ciloleucel) are advanced therapies for blood cancer. They belong to a new generation of personalised cancer immunotherapies that are based on collecting and modifying patients’ own immune cells to treat their cancer.